TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6527754
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg nitrazepam
Study: 30148660
Drug: Children with
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with ADHD (no medication)
Study: 21247745
Drug: Atenolol (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (after one-week treatment)
Study: 15988705
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg/d
Study: 15988705
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of raloxifene 60 mg/d and simvastatin 10 mg/d
Study: 7572582
Drug: Mibefradil 100
Normalized name: mibefradil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil 100 mg
Study: 10336572
Drug: Control (baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (baseline beta-adrenoceptor blocker treatment)
Study: 10336572
Drug: Mibefradil (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil (both doses)
Study: 12097764
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg twice a day for 10 days
Study: 7573719
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg twice a day for 14 days
Study: 2007671
Drug: Topical immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical immunotherapy (diphenylcyclopropenone)
Study: 2007671
Drug: Control (unilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (unilateral treatment side)
Study: 7132464
Drug: Experimental clinics
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental clinics with age-specific checklists and weekly seminars
Study: 29654498
Drug: Coffee robusta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee robusta sachet dissolved in 100 ml of hot water
Study: 29654498
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml water only
Study: 20035353
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (15 patients laparoscopic, 22 patients open)
Study: 16160619
Drug: St John's
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St John's wort (900 mg/d)
Study: 9176086
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg GTN (0.5 mg/ml)
Study: 9176086
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg GTN (1 mg/ml)
Study: 8458531
Drug: gemfibrozil 1200
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gemfibrozil 1200 mg daily for 12 weeks
Study: 3426682
Drug: Calcium carbimide
Normalized name: calcium carbimide
DrugBank: Calcium carbimide (DB09116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium carbimide (50 mg)
Study: 22339708
Drug: Tremella mesenterica
Normalized name: Tremella fuciformis whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremella mesenterica (Tm) 2 g
Study: 22339708
Drug: Tremella mesenterica
Normalized name: Tremella fuciformis whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremella mesenterica (Tm) with omeprazole 20 mg
Study: 22339708
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg, clarithromycin 500 mg, and amoxicillin 1000 mg (standard triple therapy)
Study: 20556775
Drug: Inhaled oxygen
Normalized name: oxygen Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled oxygen (at normal pressure)
Study: 16044078
Drug: Nicorandil (4‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (4‐6 mg/h)
Study: 12182991
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg q.i.d. for 7 days
Study: 8582435
Drug: etofibrate 500
Normalized name: etofibrate 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etofibrate 500 mg/day for 5 days
Study: 8582435
Drug: bezafibrate 400
Normalized name: bezafibrate 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate 400 mg/day for 5 days
Study: 2153424
Drug: R68070 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: R68070 (400 mg)
Study: 2153424
Drug: Aspirin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (400 mg)
Study: 7029741
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amoxycillin and flucloxacillin (Suprapen; Bencard)
Study: 7029741
Drug: Antibiotics only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics only if postoperative sepsis developed (Control)
Study: 28698331
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment (ART) using high-viscosity glass ionomer cement
Study: 18422764
Drug: Duloxetine 40
Normalized name: duloxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 40 mg twice daily
Study: 17498126
Drug: Benazepril (2.5-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (2.5-5 mg)
Study: 16177001
Drug: Pilocarpine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine (5 mg oral solution)
Study: 7608283
Drug: Beta-blocker bisoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker bisoprolol (4.25 +/- 1.2 mg/day) for 4 months
Study: 7608283
Drug: Levothyroxine (L-T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (L-T4) therapy
Study: 2172309
Drug: Diet-laxative (DL)
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet-laxative (DL) group
Study: 6820492
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of 1500 mg sodium valproate
Study: 6820492
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of 1500 mg sodium valproate
Study: 26721141
Drug: Relaxing needling
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxing needling manipulation combined with exercise therapy (Group A)
Study: 26721141
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (Group B)
Study: 23795874
Drug: Buprenorphine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine treatment (cocaine users)
Study: 19124099
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg iodine/ml (Iopromide 300)
Study: 19124099
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg iodine/ml (Iomeprol 400)
Study: 15804728
Drug: Low-dose hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose hormone therapy (HT)
Study: 12470755
Drug: latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: latanoprost 0.005% once daily
Study: 12470755
Drug: unoprostone 0.15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: unoprostone 0.15% twice daily
Study: 2889957
Drug: APD (aminohydroxy-propylidene-bisphosphonate),
Approvals — FDA: no, EMA: no, PMDA: no
Description: APD (aminohydroxy-propylidene-bisphosphonate), 300 mg daily (n = 70)
Study: 12207762
Drug: Dead Sea
Normalized name: Cleanser Topical application Soap [MG217 DEAD SEA SOAP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dead Sea climatotherapy/pseudocatalase cream (PC-KUS)
Study: 12207762
Drug: Dead Sea
Normalized name: Cleanser Topical application Soap [MG217 DEAD SEA SOAP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dead Sea climatotherapy/placebo cream
Study: 12207762
Drug: Conventional pseudocatalase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pseudocatalase monotherapy
Study: 12207762
Drug: Narrowband UVB
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Narrowband UVB activated pseudocatalase cream (PC-KUS)
Study: 27281373
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for SAD (CBT-SAD)
Study: 27033936
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide releasing solution (NORS)
Study: 27033936
Drug: Tilmicosin (macrolide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilmicosin (macrolide antibiotic)
Study: 20300753
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy (methylprednisolone)
Study: 16006882
Drug: Diclofenac suppository
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac suppository (DS)
Study: 16006882
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lidocaine PPNB and DS
Study: 12479658
Drug: Adjunctive antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive antidepressant
Study: 10342350
Drug: Active ultrasound
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ultrasound treatment (20 minutes daily for 75 days)
Study: 10342350
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (20 minutes daily for 75 days)
Study: 10342350
Drug: Active ultrasound
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ultrasound treatment
Study: 7718317
Drug: Weekly 20
Normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly 20 mg mitoxantrone intravesically for 6 weeks after TUR
Study: 7185773
Drug: Prazepam (tranquillizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazepam (tranquillizing agent)
Study: 31039579
Drug: Prefrontal tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prefrontal tDCS (transcranial direct current stimulation) administered to the left prefrontal cortex prior to CBT for eight weekly sessions
Study: 28427826
Drug: Suvorexant 15
Normalized name: suvorexant 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suvorexant 15 mg
Study: 28427826
Drug: Suvorexant 30
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suvorexant 30 mg
Study: 23829494
Drug: Racemic salbutamol
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic salbutamol (200 μg q.i.d.)
Study: 23829494
Drug: Levosalbutamol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosalbutamol (100 μg q.i.d.)
Study: 19003983
Drug: Etoposide (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide (single agent)
Study: 15893351
Drug: Killed whole‐cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed whole‐cell Leishmania amazonensis vaccine (3 doses at 20-day intervals)
Study: 15893351
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 doses at 20-day intervals)
Study: 7511324
Drug: Dextran-coated superparamagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran-coated superparamagnetic iron oxide particles (BMS 180549) at a dose of 1.7 mg Fe/kg
Study: 7511324
Drug: Dextran-coated superparamagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran-coated superparamagnetic iron oxide particles (BMS 180549) at doses ranging from 0.3 to 1.7 mg Fe/kg
Study: 28158524
Drug: Participatory trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participatory trial intervention (details on dosage and duration not available)
Study: 25582785
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lidocaine and bupivacaine
Study: 20183690
Drug: Guided Internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Internet-delivered self-help treatment (5 weekly text modules, video exposure, Internet support)
Study: 20183690
Drug: Live-exposure treatment
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live-exposure treatment (1 session of 3 hours following a brief orientation)
Study: 16929589
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of interferon alfa-2b plus ribavirin for 48 weeks
Study: 16929589
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of interferon alfa-2b plus ribavirin
Study: 11087644
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (pre-operative and intraoperative radiotherapy)
Study: 8967308
Drug: Non-fractioned heparin
Normalized name: OMIDUBICEL NON-CULTURED FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fractioned heparin (Liquemine)
Study: 8967308
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Fraxiparine)
Study: 4083303
Drug: Evening dosing
Normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dosing with Uniphyl (10 P.M.)
Study: 4083303
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing with Uniphyl (8 A.M.)
Study: 23534865
Drug: Folate-fortified oral
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate-fortified oral contraceptive (OC)
Study: 23534865
Drug: Marketed oral
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed oral contraceptive (OC)
Study: 22640829
Drug: Bevacizumab 10
Normalized name: bevacizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 10 mg/kg days 1 and 15; paclitaxel 90 mg/m(2) days 1, 8, and 15, every 4 weeks (Arm A)
Study: 22640829
Drug: Bevacizumab 15
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg day 1; capecitabine 1000 mg/m(2) b.i.d., days 1‐14, every 3 weeks (Arm B)
Study: 15246599
Drug: 23-valent polysaccharide
Normalized name: pneumococcal 23-valent polysaccharide vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent polysaccharide vaccine
Study: 1661490
Drug: Transcranial electric
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transcranial electric stimulation (TES) combined with pharmacotherapy (group I)
Study: 6762889
Drug: Pirenzepine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (50 mg three times a day for 4 weeks)
Study: 25192282
Drug: Low-dose helical
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose helical CT scan for lung cancer screening (NLST)
Study: 22958426
Drug: Taspoglutide 10
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taspoglutide 10 mg
Study: 22958426
Drug: Taspoglutide 20
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taspoglutide 20 mg
Study: 16733277
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for giardiasis
Study: 11020032
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of drugs taken prior to admission
Study: 11020032
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of drugs received during hospitalization
Study: 11020032
Drug: Importance rating
Normalized name: Aratinga erythrogenys feather extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Importance rating of drug characteristics
Study: 11020032
Drug: Sources of
Normalized name: Dental Resources brand of Stannous Fluoride Dental Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sources of drug information
Study: 9032890
Drug: Lipoprotein OspA
Normalized name: Lipoprotein OspA antigen recombinant
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipoprotein OspA vaccine
Study: 9032890
Drug: Unlipidated OspA
Normalized name: OspA protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unlipidated OspA vaccine
Study: 9032890
Drug: Lipidated OspA
Normalized name: OspA protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipidated OspA vaccine
Study: 1891755
Drug: TXA2 synthetase
Normalized name: nitric oxide synthase
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA2 synthetase inhibitor (Cataclot) administered to 13 patients by continuous drip infusion at a dose of 1 microgram/kg/min for 8 to 14 days (group A)
Study: 19257800
Drug: Aliskiren/amlodipine 300/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren/amlodipine 300/10 mg
Study: 22303911
Drug: Aliskiren/amlodipine 150/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren/amlodipine 150/10 mg
Study: 19914303
Drug: Cefaclor (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (1000 mg)
Study: 17516958
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate tablet (150 g tablet, containing 50 mg of elemental iron) daily throughout pregnancy
Study: 16271570
Drug: Forced-use therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forced-use therapy (FUT) combined with conventional rehabilitation program
Study: 9659093
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml 75% sucrose solution
Study: 2556172
Drug: Lisinopril 80
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril 80 mg once daily
Study: 2556172
Drug: Lisinopril 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 1.25 mg once daily
Study: 2556172
Drug: Lisinopril 5
Normalized name: lisinopril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 5 mg once daily
Study: 31423822
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care and electrical stimulation to wrist flexors and extensors for 30 minutes, twice a day, five days a week for three months
Study: 19843803
Drug: Gabapentin 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 1.2 g and bolus plus infusion of saline
Study: 19843803
Drug: Ketamine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.3 mg/kg IV bolus and 0.05 mg/kg/h infusion until the end of surgery
Study: 19843803
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received oral placebo capsules and bolus plus infusion of saline
Study: 18269691
Drug: Drotrecogin alfa
Normalized name: Drotrecogin Alfa
DrugBank: Drotrecogin alfa (DB00055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotrecogin alfa (activated; DrotAA) at standard therapy (24 mug/kg per hour for 96 hours)
Study: 18269691
Drug: Drotrecogin alfa
Normalized name: Drotrecogin Alfa
DrugBank: Drotrecogin alfa (DB00055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotrecogin alfa (activated; DrotAA) at alternative therapy (higher dose with variable infusion duration or variable infusion duration only)
Study: 18269691
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (DrotAA)
Study: 18269691
Drug: Alternative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative therapy (DrotAA)
Study: 18269691
Drug: DrotAA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DrotAA therapy
Study: 11679387
Drug: Metformin usage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin usage in intervention group
Study: 27517958
Drug: Protein breakfast
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein breakfast (PRO; 350 kcal; 39 g CHO, 30 g PRO, 8 g fat)
Study: 27517958
Drug: Carbohydrate breakfast
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate breakfast (CHO; 351 kcal; 59 g CHO, 10 g PRO, 8 g fat)
Study: 21927920
Drug: Denosumab 14
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab 14 mg
Study: 21927920
Drug: Denosumab 100
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab 100 mg
Study: 21927920
Drug: Denosumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (all doses)
Study: 19098692
Drug: Intramuscular acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular acupuncture
Study: 12534029
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg of betamethasone (12 mg every 24 hours)
Study: 3480840
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of oxytocin
Study: 28836381
Drug: Tongue cleaning
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongue cleaning with mouth moisturising gel
Study: 24898233
Drug: Daily breakfast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily breakfast (≥700 kcal before 1100)
Study: 21765272
Drug: Multimodal physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal physical therapy program plus deep-water running
Study: 21765272
Drug: Multimodal physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal physical therapy program alone
Study: 11742706
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus vinorelbine (G+V) 1200 mg/m(2) plus 30 mg/m(2) on days 1 and 8 every 3 weeks
Study: 11742706
Drug: Vinorelbine (V)
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine (V) 30 mg/m(2) on days 1 and 8 every 3 weeks